Jul. 21 at 4:11 PM
When you see
$PPBT thrown into lists alongside
$ALXO $JANX $CUE $HOWL, that’s not analysis—it’s camouflage. It’s a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data.
💥 Purple Biotech stands alone:
• Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients.
• CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation.
• Cash runway to 2026, focused pipeline, expanding IP, and a strategy that’s quietly creating asymmetrical upside.
These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets.
Don’t let ticker bundling blur the signal. This biotech isn’t rising with the tide—it’s cutting through it. 🧬👊
